Taysha Gene Therapies, Inc. TSHA Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $9.77M+17.3% | $8.33M-46.1% | $15.45M+518% | $2.5M— | ||
| $86.4M+30.9% | $66M+16.2% | $56.78M-37.7% | $91.17M-30.9% | ||
| $33.87M+17.0% | $28.95M-3.6% | $30.05M-19.6% | $37.36M-9.6% | ||
| —— | —— | —— | $36.42M— | ||
| $120.27M+20.5% | $99.79M+13.5% | $87.89M-46.7% | $164.95M-4.8% | ||
| $120.27M+20.5% | $99.79M+13.5% | $87.89M-46.7% | $164.95M-4.8% | ||
| -$110.5M-20.8% | -$91.46M-26.3% | -$72.44M+55.4% | -$162.45M+6.2% | ||
| -1,130.6%-33.1pp | -1,097.6%-629pp | -468.8%+6,024pp | -6,492.7%— | ||
| $63K-38.2% | $102K-98.0% | $5M+31.6% | $3.8M+166% | ||
| $9.22M+32.9% | $6.94M— | —— | —— | ||
| $1.5M-30.4% | $2.16M— | —— | -$3.57M-184% | ||
| —— | —— | -$1.4M— | —— | ||
| -$109M-22.1% | -$89.3M— | —— | -$166.01M+4.9% | ||
| -1,115.3%-43.6pp | -1,071.6%— | —— | -6,635.3%— | ||
| -$0.34+5.6% | -$0.36— | —— | -$3.81+17.9% | ||
| -$0.34+5.6% | -$0.36— | —— | -$3.81+17.9% | ||
| 1.2B+26.3% | 982M+166% | 369.3M+126% | 163.2M+8.7% | ||
| 1.2B+26.3% | 982M+166% | 369.3M+126% | 163.2M— | ||
| $6.17M+34.6% | $4.58M+198% | $1.54M— | —— | ||
| $1.2M+7,594% | -$16K— | —— | —— | ||
| -$291K-165% | -$110K-134% | -$47K-161% | -$18K— | ||
| -$110.5M-20.8% | -$91.46M-26.3% | -$72.44M+55.4% | -$162.45M+6.2% | ||
| -$109.42M-21.3% | -$90.23M-27.0% | -$71.04M+55.9% | -$161.23M+6.7% | ||
| -$109.42M-21.3% | -$90.23M-27.0% | -$71.04M+55.9% | -$161.23M+6.7% | ||
| -1,119.6%-36.8pp | -1,082.8%-623pp | -459.8%+5,984pp | -6,443.8%— | ||
| -$110.5M-20.8% | -$91.46M-26.3% | -$72.44M+55.4% | -$162.45M+6.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Taysha Gene Therapies, Inc.'s income statement data come from?
- Every line is extracted from Taysha Gene Therapies, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.